A cannabinoid neuropathic treatment that provided pain relief in rats for a period of eleven days after the oral administration of a single dose has received a patent and signed an intellectual property license with GB Sciences, Inc.
Next up, they will work on formulations based on polymer nanoparticles with active ingredients developed by GB Sciences for the treatment of chronic pain in hopes it will be suitable for humans.
The researchers Lucía Martín Banderas and Mercedes Fernández Arévalo, from the I+DNanomed research group at the University of Seville, in collaboration with the researchers J.A. Micó and E. Berrocoso, of the University of Cadiz and the Mental Health Networking Biomedical Research Centre (CIBERSAM), will develop formulations based on polymer nanoparticles with active ingredients developed by GB Sciences for the treatment of chronic pain. The researchers say use of nanotechnology allows them to encapsulate the main active ingredients in a polymer matrix composite. In this way, it is possible to extend the therapeutic effect while reducing the dose of medicine it is necessary to administer. In addition, the active ingredients cannot cross the blood-brain barrier, which removes any potential psychoactive effect.
They say their system has proven to be more effective than other methods, such as inhalation or ingestion, for administering these composites.
Part of the results of this project have recently been published in Nanomedicine: Nanotechnology, Biology and Medicine.